BioMarin Pharmaceutical Inc. (BMRN) Stifel 2026 Healthcare Conference 2026 November 11, 2026 3:20 PM EST
Company Participants
Brian Mueller – CFO & Executive VP of Finance
Gregory Friberg – Executive VP and Chief Research & Development Officer
Conference Call Participants
Paul Matteis – Stifel, Nicolaus & Company, Incorporated, Research Division
Presentation
Paul Matteis
Stifel, Nicolaus & Company, Incorporated, Research Division
All right. Great. Thanks very much. Happy to be moderating a chat here with the BioMarin management team. I think Brian, CFO, which I’m sure everybody knows, is going to make some opening remarks. And then I think we’re going to use this as an opportunity to spend some time with Greg and talk more about the pipeline that BioMarin is building out. So please take it away, Brian.
Brian Mueller
CFO & Executive VP of Finance
Thank you. Thanks, Paul. Appreciate it. Thanks for having us. Good afternoon, everyone. Yes. So some opening remarks. We’re just a week out of our Q3 report and lots of strong progress and results this year. We are executing on one of the core elements of our strategy, which is using our financial strength to fund future innovation. Very strong Q3 with revenue growth of 32%. We reached $1 billion of total revenue for the first time in the company history. A lot of that was driven by our metabolic conditions business unit with 44% growth. We’re also growing earnings per share and profitability.
One note there is that we have had 2 acquisitions in the third quarter, which are driving some level of in-process research and development expense. A lot of our growth is being driven by the recent acquisition of Amicus Therapeutics that brought 2 high-growth rare disease assets into our metabolic conditions portfolio. That is Galafold for Fabry disease and Pombiliti and Opfolda
